Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.55 -0.6%	$1.86	$1.32 ▼ $4.45	$336.76M	1.02	3.14 million shs	2.01 million shs
ARCT Arcturus Therapeutics	$11.58 -3.5%	$15.61	$11.39 ▼ $45.00	$314.05M	2.96	456,201 shs	311,032 shs
ATXS Astria Therapeutics	$5.70 -5.9%	$6.81	$5.68 ▼ $14.04	$341.99M	0.69	404,494 shs	163,052 shs
CRDL Cardiol Therapeutics	$0.96 -3.4%	$1.21	$0.91 ▼ $3.12	$79.31M	0.95	387,174 shs	550,842 shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-4.32%	-20.51%	-29.22%	-65.25%
ARCT Arcturus Therapeutics	0.00%	-10.09%	-27.80%	-31.96%	-64.76%
ATXS Astria Therapeutics	0.00%	-11.08%	-9.67%	-37.70%	-58.09%
CRDL Cardiol Therapeutics	0.00%	-14.29%	-18.64%	-26.72%	-46.67%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.031 of 5 stars	3.5	2.0	2.8	4.2	0.6
ARCT Arcturus Therapeutics	3.0487 of 5 stars	4.6	0.0	3.2	2.5	0.6
ATXS Astria Therapeutics	1.7118 of 5 stars	3.6	0.0	3.2	1.7	0.0
CRDL Cardiol Therapeutics	2.7253 of 5 stars	3.6	4.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$9.29	499.28% Upside
ARCT Arcturus Therapeutics	3.13	Buy	$59.20	411.23% Upside
ATXS Astria Therapeutics	3.29	Buy	$26.60	366.67% Upside
CRDL Cardiol Therapeutics	3.29	Buy	$8.40	775.00% Upside

Current Analyst Ratings Breakdown

Latest CRDL, ALLO, ARCT, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
3/14/2025	ALLO Allogene Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/12/2025	ATXS Astria Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00 ➝ $28.00
3/11/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00
3/7/2025	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$58.00 ➝ $50.00

(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	15,307.31	N/A	N/A	$3.04 per share	0.51
ARCT Arcturus Therapeutics	$138.39M	2.27	N/A	N/A	$10.42 per share	1.11
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.33 per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.32 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.33	N/A	N/A	N/A	N/A	-52.13%	-41.29%	5/12/2025 (Estimated)
ARCT Arcturus Therapeutics	-$29.73M	-$3.01	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	5/6/2025 (Estimated)
ATXS Astria Therapeutics	-$72.89M	-$1.67	N/A	N/A	N/A	N/A	-43.58%	-29.36%	5/8/2025 (Estimated)
CRDL Cardiol Therapeutics	-$20.84M	-$0.39	N/A	N/A	N/A	N/A	-194.40%	-129.07%	4/7/2025 (Estimated)

Latest CRDL, ALLO, ARCT, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/7/2025	N/A	CRDL Cardiol Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/11/2025	Q4 2024	ATXS Astria Therapeutics	-$0.45	-$0.44	+$0.01	-$0.44	N/A	N/A
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	6.17%	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
ARCT Arcturus Therapeutics	N/A	4.76	4.76
ATXS Astria Therapeutics	N/A	22.38	22.38
CRDL Cardiol Therapeutics	0.01	2.49	2.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ARCT Arcturus Therapeutics	94.54%
ATXS Astria Therapeutics	98.98%
CRDL Cardiol Therapeutics	12.49%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	24.30%
ARCT Arcturus Therapeutics	15.30%
ATXS Astria Therapeutics	2.90%
CRDL Cardiol Therapeutics	5.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	217.27 million	158.72 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
ATXS Astria Therapeutics	30	56.43 million	54.80 million	Optionable
CRDL Cardiol Therapeutics	20	82.61 million	78.27 million	Not Optionable

CRDL, ALLO, ARCT, and ATXS Headlines

Recent News About These Companies

Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Average Recommendation of "Buy" by Brokerages

March 24, 2025 | americanbankingnews.com

Tejara Capital Ltd Buys 1,344,167 Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL)

March 19, 2025 | marketbeat.com

Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Average Recommendation of "Buy" from Brokerages

March 19, 2025 | marketbeat.com

Short Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Increases By 26.4%

March 18, 2025 | marketbeat.com

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

March 3, 2025 | newsfilecorp.com

Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure

February 20, 2025 | proactiveinvestors.com

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

February 20, 2025 | newsfilecorp.com

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

February 19, 2025 | seekingalpha.com

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | newsfilecorp.com

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

January 31, 2025 | zacks.com

Cardiol Therapeutics initiated with a Buy at Rodman & Renshaw

January 28, 2025 | markets.businessinsider.com

Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock

January 28, 2025 | msn.com

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

December 19, 2024 | globenewswire.com

3 Penny Stocks Ready to Break Out in 2025

November 29, 2024 | marketbeat.com

Edward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market Potential

November 21, 2024 | markets.businessinsider.com

Cardiol Therapeutics Reports Promising Phase II Results

November 18, 2024 | markets.businessinsider.com

Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy

November 18, 2024 | proactiveinvestors.com

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024 | newsfilecorp.com

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

November 13, 2024 | globenewswire.com

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

November 13, 2024 | prismmediawire.com

Cardiol Therapeutics’ Strategic Advancements Boost Market Potential and Revenue Projections

October 24, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

2 Energy Stocks to Play Both Sides of Tariff Uncertainty
By Jea Yu | March 5, 2025
View 2 Energy Stocks to Play Both Sides of Tariff Uncertainty
These 3 Big Banks Are Set to Gain as Consumers Stash More Cash
By Gabriel Osorio-Mazilli | March 7, 2025
View These 3 Big Banks Are Set to Gain as Consumers Stash More Cash
Oklo’s Stock Price Meltdown Is an Opportunity to Buy
By Thomas Hughes | March 25, 2025
View Oklo’s Stock Price Meltdown Is an Opportunity to Buy
How to Protect Your Portfolio When Inflation Is Rising
By Sarah Horvath | March 10, 2025
View How to Protect Your Portfolio When Inflation Is Rising
Semtech Rallies on Earnings Beat—Is There More Upside?
By Leo Miller | March 20, 2025
View Semtech Rallies on Earnings Beat—Is There More Upside?

CRDL, ALLO, ARCT, and ATXS Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.55 -0.01 (-0.64%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$1.58 +0.03 (+2.19%)

As of 03/28/2025 07:02 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Arcturus Therapeutics NASDAQ:ARCT

$11.58 -0.42 (-3.50%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$11.59 +0.01 (+0.08%)

As of 03/28/2025 07:53 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Astria Therapeutics NASDAQ:ATXS

$5.70 -0.36 (-5.94%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$5.70 0.00 (0.00%)

As of 03/28/2025 06:25 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$0.96 -0.03 (-3.38%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.04 (+4.17%)

As of 03/28/2025 07:56 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time